BioSpace News Archive

Sotera Health Company announced that Alex Dimitrief is joining the Company as Senior Vice President and General Counsel.

Cara Therapeutics, Inc. announced that members of its Executive Leadership Team will present at the following investor conferences.

Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, reported financial results for the third quarter of 2022 and highlighted recent achievements and developments.

Omega Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for OTX-2002, the company’s first-in-class epigenomic controller engineered to downregulate c-Myc (MYC), for the treatment of hepatocellular carcinoma (HCC).

Vaccitech plc announced that the Company will be presenting an update on its Phase 1b/2a study of VTP-300, Vaccitech’s novel immunotherapy for chronic hepatitis B, at the American Association for the Study of Liver Disease - The Liver Meeting®, in Washington, D.C., November 4 – 8, 2022.

Immutep Limited announces a late-breaking abstract relating to its phase II TACTI-002 trial has been accepted for an oral presentation at the Society for Immunotherapy of Cancer Annual Meeting 2022.

Oyster Point Pharma, Inc., announced that the Compensation Committee of the Company’s Board of Directors granted inducement non-qualified stock options to purchase an aggregate of 14,400 shares of common stock to seven new employees, pursuant to the Oyster Point Pharma, Inc., 2021 Inducement Incentive Plan.

scPharmaceuticals Inc. announced that John Tucker, President & Chief Executive Officer, is scheduled to present at the Jefferies London Healthcare Conference, on Wednesday, November 16 at 5:35 pm GMT.

Bluestar Genomics, Inc. today announced the results of a validation study for its early pancreatic cancer detection test.

Ocuphire Pharma, Inc. today announced that the positive results in night vision disturbances (NVD) patients from its earlier and first Phase 2 study evaluating the safety and efficacy of phentolamine mesylate eye drops (Nyxol).